Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 567

1.

YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity.

Sugihara T, Werneburg NW, Hernandez MC, Yang L, Kabashima A, Hirsova P, Yohanathan L, Sosa C, Truty MJ, Vasmatzis G, Gores GJ, Smoot RL.

Mol Cancer Res. 2018 Jun 14. doi: 10.1158/1541-7786.MCR-18-0158. [Epub ahead of print]

PMID:
29903769
2.

Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma.

Rizvi S, Eaton J, Yang JD, Chandrasekhara V, Gores GJ.

Semin Liver Dis. 2018 May;38(2):160-169. doi: 10.1055/s-0038-1655775. Epub 2018 Jun 5.

PMID:
29871021
3.

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.

Guicciardi ME, Trussoni CE, Krishnan A, Bronk SF, Lorenzo Pisarello MJ, O'Hara SP, Splinter PL, Gao Y, Vig P, Revzin A, LaRusso NF, Gores GJ.

J Hepatol. 2018 Sep;69(3):676-686. doi: 10.1016/j.jhep.2018.05.018. Epub 2018 May 24.

PMID:
29802947
4.

Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes in PSC: A Derivation & Validation Study Using Machine Learning.

Eaton JE, Vesterhus M, McCauley BM, Atkinson EJ, Schlicht EM, Juran BD, Gossard AA, LaRusso NF, Gores GJ, Karlsen TH, Lazaridis KN.

Hepatology. 2018 May 9. doi: 10.1002/hep.30085. [Epub ahead of print]

PMID:
29742811
5.

Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking through a Door Half-opened.

Rizvi S, Gores GJ.

Hepatology. 2018 Apr 27. doi: 10.1002/hep.30069. [Epub ahead of print] No abstract available.

PMID:
29704257
6.

Does cirrhosis associated with well controlled viral hepatitis confer a risk for extrahepatic cancer?

Yang JD, Gores GJ.

Hepatology. 2018 Apr 26. doi: 10.1002/hep.30063. [Epub ahead of print] No abstract available.

PMID:
29698552
7.

Animal models of cholangiocarcinoma.

Loeuillard E, Fischbach SR, Gores GJ, Rizvi S.

Biochim Biophys Acta. 2018 Apr 5. pii: S0925-4439(18)30124-8. doi: 10.1016/j.bbadis.2018.03.026. [Epub ahead of print] Review.

PMID:
29627364
8.

YAP-associated chromosomal instability and cholangiocarcinoma in mice.

Rizvi S, Fischbach SR, Bronk SF, Hirsova P, Krishnan A, Dhanasekaran R, Smadbeck JB, Smoot RL, Vasmatzis G, Gores GJ.

Oncotarget. 2017 Dec 22;9(5):5892-5905. doi: 10.18632/oncotarget.23638. eCollection 2018 Jan 19.

9.

Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.

Kabashima A, Hirsova P, Bronk SF, Hernandez MC, Truty MJ, Rizvi S, Kaufmann SH, Gores GJ.

J Hepatol. 2018 Jun;68(6):1228-1238. doi: 10.1016/j.jhep.2018.01.026. Epub 2018 Mar 9.

PMID:
29408314
10.

Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.

Ibrahim SH, Hirsova P, Gores GJ.

Gut. 2018 May;67(5):963-972. doi: 10.1136/gutjnl-2017-315691. Epub 2018 Jan 24. Review.

11.

TRAIL Deletion Prevents Liver, but Not Adipose Tissue, Inflammation during Murine Diet-Induced Obesity.

Hirsova P, Weng P, Salim W, Bronk SF, Griffith TS, Ibrahim SH, Gores GJ.

Hepatol Commun. 2017 Sep;1(7):648-662. doi: 10.1002/hep4.1069. Epub 2017 Jul 20.

12.

The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis.

Puri P, Liangpunsakul S, Christensen JE, Shah VH, Kamath PS, Gores GJ, Walker S, Comerford M, Katz B, Borst A, Yu Q, Kumar DP, Mirshahi F, Radaeva S, Chalasani NP, Crabb DW, Sanyal AJ; TREAT Consortium.

Hepatology. 2018 Apr;67(4):1284-1302. doi: 10.1002/hep.29623. Epub 2018 Feb 22.

13.

Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis.

Yang JD, Mannalithara A, Piscitello AJ, Kisiel JB, Gores GJ, Roberts LR, Kim WR.

Hepatology. 2018 Jul;68(1):78-88. doi: 10.1002/hep.29594. Epub 2018 May 9.

PMID:
29023828
14.

Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ.

Nat Rev Clin Oncol. 2018 Feb;15(2):95-111. doi: 10.1038/nrclinonc.2017.157. Epub 2017 Oct 10. Review.

15.

Primary Sclerosing Cholangitis: What the Gastroenterologist and Hepatologist Needs to Know.

Gossard AA, Gores GJ.

Clin Liver Dis. 2017 Nov;21(4):725-737. doi: 10.1016/j.cld.2017.06.004. Epub 2017 Jul 25. Review.

PMID:
28987259
16.

Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary sclerosing cholangitis.

Loarca L, De Assuncao TM, Jalan-Sakrikar N, Bronk S, Krishnan A, Huang B, Morton L, Trussoni C, Bonilla LM, Krueger E, O'Hara S, Splinter P, Shi G, Pisarello MJL, Gores GJ, Huebert RC, LaRusso NF.

Lab Invest. 2017 Nov;97(11):1385-1396. doi: 10.1038/labinvest.2017.63. Epub 2017 Sep 11.

17.

Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.

Greuter T, Malhi H, Gores GJ, Shah VH.

JCI Insight. 2017 Sep 7;2(17). pii: 95354. doi: 10.1172/jci.insight.95354. [Epub ahead of print] Review.

18.

Targeting cholangiocarcinoma.

Mertens JC, Rizvi S, Gores GJ.

Biochim Biophys Acta. 2018 Apr;1864(4 Pt B):1454-1460. doi: 10.1016/j.bbadis.2017.08.027. Epub 2017 Aug 24. Review.

19.

PPAR agonists for primary biliary cholangitis.

Gossard AA, Gores GJ.

Lancet Gastroenterol Hepatol. 2017 Oct;2(10):693-694. doi: 10.1016/S2468-1253(17)30256-X. Epub 2017 Aug 14. No abstract available.

PMID:
28818517
20.

Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/- ) mice.

Moncsek A, Al-Suraih MS, Trussoni CE, O'Hara SP, Splinter PL, Zuber C, Patsenker E, Valli PV, Fingas CD, Weber A, Zhu Y, Tchkonia T, Kirkland JL, Gores GJ, Müllhaupt B, LaRusso NF, Mertens JC.

Hepatology. 2018 Jan;67(1):247-259. doi: 10.1002/hep.29464. Epub 2017 Nov 29.

PMID:
28802066

Supplemental Content

Loading ...
Support Center